CD274 and non-small cell lung carcinoma: The first‐line therapeutic regimens are now recommended for advanced patients without oncogene‐driven NSCLC, including pembrolizumab, atezolizumab, and cemiplimab monotherapy (PD‐L1 ≥ 50%), chemotherapy alone, or combination therapy based on platinum‐based chemotherapy.5